Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | PLK4 | O00444 | 4/20 | 0.45 |
| ▸ | PLK1 | P53350 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 3/20 | 0.44 |
| ▸ | KIT | P10721 | 3/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3795730 | 1.00 | GSK3B (0.58) | GSK3BCHEK1KDRPLK4PLK1 | |
| SCHEMBL3712948 | 1.00 | GSK3B (0.58) | GSK3BCHEK1KDRPLK4PLK1 | |
| SCHEMBL3408038 | 1.00 | GSK3B (0.58) | GSK3BCHEK1KDRPLK4PLK1 | |
| SCHEMBL6533149 | 0.91 | MAPT (0.49) | GSK3BCHEK1KDRPLK4PLK1 | |
| SCHEMBL12795260 | 0.91 | GSK3B (0.48) | GSK3BCHEK1KDRPLK4MAPT | |
| SCHEMBL6533146 | 0.91 | MAPT (0.49) | GSK3BCHEK1KDRPLK4PLK1 | |
| SCHEMBL12795313 | 0.91 | MAPT (0.49) | GSK3BCHEK1KDRPLK4PLK1 | |
| SCHEMBL6523915 | 0.89 | CHEK1 (0.50) | GSK3BCHEK1KDRPLK4MAPT | |
| SCHEMBL6523924 | 0.89 | CHEK1 (0.50) | GSK3BCHEK1KDRPLK4MAPT | |
| SCHEMBL6531026 | 0.88 | TLK2 (0.48) | GSK3BCHEK1KDRPLK4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20130123273-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
| EP-2235004-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | University Health Network (CA) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009079767-A9 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079767-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123273-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | PTEN, PIK3CA, HRAS | GSK3B 141/4885CHEK1 360/4885KDR 656/4885 |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | GSK3B 621/4885CHEK1 97/4885KDR 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.